Andrew M. Evens, Deputy Director for Clinical Services at Rutgers Cancer Institute, shared a post on LinkedIn:
“Happy to discuss our pubication in the NEJM Group Evidence: the Early-Stage Hodgkin International Prognostic Index (aka the EHIPI) prediction model
- Using Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) guidelines in a 3,000 early-stage HL development cohort from 4 seminal phase III clinical trials w/ validation from 2 external cohorts, totaling >2,300 pts from 5 global ‘real world’ HL registries. manuscript here
- The 4 variables retained in the final E-HIPI model were: sex, CONTINUOUS values of maximum tumor diameter (MTD), and continuos values of hemoglobin and albumin.
- Additionally, higher-risk E-HIPI scores were associated with worse outcomes in both the EORTC unfavorable and favorable subgroups. And when included altogether in 1 Cox model, the EHIPI was associated with PFS, whereas EORTC favorable/unfavorable status was not.
- Finally, an interactive online tool for the E-HIPI that generates 2-year PFS in an individualized risk calculator, and also dynamic applications for risk comparison and risk stratification across user-defined cut-off points (SEE the 3 calculators HERE: https://lnkd.in/eyZmk7De).
We thank the entire Global HoLSITIC consortium members (Hodgkin Lymphoma International Study for Individual Care) for their incredible collaboration. The HoLISTIC datacommons now contains >30,000 individual cases; MUCH more work is ongoing and planned!”
Title: An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma
Authors: Angie Mae Rodday, Andrew M. Evens, Matthew J. Maurer, Jenica N. Upshaw, Nicholas Counsell, Sara Rossetti, Cheryl Chang, Zhu Cui, Qingyan Xiang, Raphael Mwangi, Ranjana Advani, Marc Andre, Andrea Gallamini, Annette E. Hay, David C. Hodgson, Richard T. Hoppe, Martin Hutchings, Peter Johnson, Eric Mou, Stephen Opat, John Raemaekers, Kerry J. Savage, Susan K. Parsons and John Radford.
Other articles featuring Andrew M. Evens on OncoDaily.